AI-assisted, human-published
10/28/2024 /M & A
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
AbbVie's acquisition of Aliada Therapeutics will facilitate the advancement of ALIA-1758, a treatment for Alzheimer's disease utilizing a unique blood-brain barrier-crossing technology, aligning with AbbVie's commitment to innovation in neuroscience.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com